Prognostic Factors in Head and Neck Cancer
Author Information
Author(s): I. Doweck, M. Barak, N. Uri, E. Greenberg
Primary Institution: Carmel Medical Center, Haifa, Israel
Hypothesis
What is the prognostic value of Cyfra 21-1 for patients with carcinoma of the head and neck?
Conclusion
Cyfra 21-1 is a prognostic factor for patients with carcinoma of the head and neck, unrelated to the stage of the disease.
Supporting Evidence
- 32 patients had low levels of Cyfra 21-1 at diagnosis, with a 63% survival rate for 40 months.
- 35 patients had Cyfra 21-1 levels above 1.5 ng/ml, with a 20% survival rate.
Takeaway
Doctors can use a blood test called Cyfra 21-1 to help predict how well patients with head and neck cancer will do, no matter how advanced their cancer is.
Methodology
The study evaluated Cyfra 21-1 levels in 67 patients with primary detection of carcinoma of the head and neck and followed their survival rates.
Participant Demographics
67 patients with primary detection of carcinoma of head and neck.
Statistical Information
P-Value
0.03
Statistical Significance
p<0.03
Want to read the original?
Access the complete publication on the publisher's website